2025年7月22日，科创板迎来开市6周年。 6年来，科创板上市公司数量已由首批挂牌上市的25家增至589家，IPO及再融资募资金额超1.1万亿元。 目前，超八成科创板公司为新一代信息技术、生物医药、高端装备制造等新兴产业公司，超八成公司核 心产品瞄准进口替代及自主可控，超380家公司的850余项产品或技术达到国际先进水平。 20家适用第五套标准上市的企业中，已有19家公司自研的45款药品/疫苗获批上市，其余1家公司产品上 市申请已获受理；16家公司营收超过1亿元，其中4家公司营收超过10亿元。2018年以来，科创板第五套 标准上市企业推出的1类新药数量约占同期国产创新药获批总数的12%，日益成长为我国医药创新的中 坚力量。 与此同时，作为改革"试验田"，科创板在发行、上市、交易、退市、再融资、并购重组等方面进行了一 系列制度创新，形成了可复制可推广的经验，为存量市场改革提供了有益借鉴。 有专家在接受《中国经营报》记者采访时总结道，科创板开市6周年以来，最大的成就是构建了一个 以"硬科技"为核心的资本市场平台，推动了科技创新与资本市场的深度融合。同时，科创板推动了资本 市场制度创新，为中国资本市场改革起到了示 ...

科创板今天（22日）迎来开市6周年。6年来，科创板以注册制改革为抓手，支持优质科技企业上市， IPO与再融资募集资金合计超1.1万亿元。记者从上海证券交易所了解到，截至7月22日，科创板累计支 持589家公司上市，IPO募集资金9257亿元，再融资募集资金1867亿元，总市值超过7万亿元。开市6年 来，科创板成为国内"硬科技"企业上市的首选地。上市公司高度聚集于高新技术产业和战略性新兴产 业，与 新质生产力发展方向高度契合。新一代信息技术、 生物医药、高端装备制造等新兴产业公司占 比超八成。 (央视新闻) ...

2025年7月22日，科创板迎来开市六周岁的生日。 作为我国资本市场改革的"试验田"和科技创新的核心枢纽，科创板六年来持续推动制度创新与产业升 级，成为全球瞩目的"硬科技"企业聚集地。 截至2025年7月22日，科创板上市公司达到589家。 科创板重点服务的战略新兴产业与新质生产力发展方向高度契合，新一代信息技术、生物医药、高端装 备制造等新兴产业公司占比超八成。经过六年的培育，科创板在集成电路、生物医药、新能源等重点产 业链形成示范和集聚效应，推动构建以行业"链主"为引领、上下游企业协同发展的矩阵式产业集群。 六年多来，上交所坚守科创板板块定位，深化各项制度机制创新，改革效应不断放大。特别是"科创板 八条"发布实施一年来，科创板改革"再出发"，服务科技创新和新质生产力发展的能力持续增强。 六年耕耘，科创板持续引领制度创新。 今年6月，"1+6"政策措施发布，统筹推进投融资综合改革和投资者权益保护，加快构建更有利于支持全 面创新的资本市场生态，揭开科创板新一轮改革序幕。 中信建投（601066）证券董事总经理董军峰在受访时表示，在科创板迈入"六年之期"的当口，设立"科 创成长层"及配套六项改革，标志着我国资本 ...

Group 1 - The Science and Technology Innovation Board (STAR Market) has celebrated its 6th anniversary, currently hosting 589 listed companies with a total market capitalization exceeding 7 trillion yuan, marking a significant growth in "hard technology" [1] - Over 60 companies on the STAR Market have launched globally innovative products, with 30% of companies having products or projects that are first of their kind, and more than 60% of companies possess over 850 products and technologies that meet international advanced standards [1] - The STAR Market has produced 35 companies ranked first globally in their respective fields, 124 companies ranked first nationally, and 196 companies ranked among the top five globally or nationally [1] Group 2 - The STAR Market has accumulated over 120,000 invention patents, with an average of 216 patents per company, and 138 projects led or participated in by 81 STAR Market companies have received major national science and technology awards [1] - The high research and development (R&D) investment has contributed to these achievements, with an average R&D intensity of over 10% since its inception, and R&D investment reaching 168.1 billion yuan in 2024, more than three times the net profit attributable to shareholders for that year, reflecting a year-on-year growth of 6.4% [1] - The median R&D investment as a percentage of operating revenue stands at 12.6%, consistently leading other sectors in the A-share market [1] Group 3 - The breakthroughs in "hard technology" are supported by the continuous improvement of the capital market's inclusive system, including the pilot registration system and reforms related to IPOs, refinancing, and mergers and acquisitions [2] - The STAR Market has raised over 1.1 trillion yuan through IPOs and refinancing, establishing itself as the preferred financing destination for "hard technology" enterprises [2] - More than 80% of the companies on the STAR Market are from emerging industries such as new generation information technology, biomedicine, and high-end equipment manufacturing, creating demonstration and clustering effects in key industrial chains like integrated circuits, biomedicine, and new energy [2]

Group 1 - The core idea of the article highlights the significant achievements of the Sci-Tech Innovation Board (STAR Market) since its establishment, emphasizing its role in supporting "hard technology" enterprises and facilitating the registration-based reform in China's capital market [1][2] - As of July 21, 2025, the STAR Market has 589 listed companies with a total market capitalization of approximately 7.4 trillion yuan, having raised over 1.1 trillion yuan in total through IPOs and refinancing [1] - The STAR Market has become a vital platform for the development of new productive forces, with a focus on strategic emerging industries such as new-generation information technology, biomedicine, and high-end equipment manufacturing, which account for over 80% of the listed companies [2] Group 2 - The compound annual growth rates for revenue and net profit attributable to shareholders of STAR Market companies are 19% and 9%, respectively, since 2019 [2] - Among the 54 unprofitable companies at the time of listing, 22 have achieved profitability post-listing, and 19 out of 20 companies listed under the fifth set of standards have received approval for their self-developed drugs/vaccines [2] - In 2024, STAR Market companies' total R&D investment reached 168 billion yuan, more than three times their net profit, with a median R&D investment-to-revenue ratio of 12.6%, leading all A-share sectors [2]

Core Viewpoint - The article emphasizes the significant progress and future potential of the Sci-Tech Innovation Board (STAR Market) in China, highlighting its role in fostering technological innovation and serving as a new high ground for new quality productivity development [1][2]. Group 1: Market Development and Structure - The STAR Market has evolved from a "testing ground" to a "demonstration site," with over 80% of listed companies in emerging industries such as new generation information technology, biomedicine, and high-end equipment manufacturing [1]. - The board has created a matrix industry cluster led by "chain masters" in key industries like integrated circuits and new energy, promoting collaborative development among upstream and downstream enterprises [1]. Group 2: Policy and Institutional Reforms - Recent reforms, including the "1+6" policy measures, aim to enhance the STAR Market's demonstration effect and further deepen capital market reforms [1][2]. - The establishment of a Sci-Tech Growth Tier within the STAR Market is designed to better serve technology-driven companies that are in the early stages of development and may not yet be profitable [3]. Group 3: Investment Ecosystem and Long-term Capital - The STAR Market is focused on building a long-term investment ecosystem, with over 60% of companies announcing cash dividend plans for 2024, totaling 38.8 billion yuan, and more than 290 companies having a cash dividend ratio exceeding 30% [2]. - The article highlights the need for a more attractive and competitive product offering in the capital market to align with the rapid technological advancements and diverse needs of tech companies [2][3]. Group 4: Future Directions and Support for Innovation - Continuous optimization of the STAR Market's listing standards and evaluation criteria is essential to support comprehensive innovation and provide more options for companies [3]. - The article advocates for enhancing financial services throughout the lifecycle of technology companies and encouraging social capital to invest early and in hard technology [3].

Core Insights - The Sci-Tech Innovation Board (STAR Market) has officially launched, with a total market value exceeding 7 trillion yuan, showcasing the emergence of strong industrial clusters in various sectors [1] - Over six years, the STAR Market has fostered 589 "hard tech" listed companies, raising over 1.1 trillion yuan in direct financing, significantly reshaping the innovation ecosystem [1] - The board has successfully transformed over 120,000 invention patents into tangible benefits for society, enhancing public welfare [1] Industry Developments - In the integrated circuit sector, a complete industrial chain covering design, manufacturing, packaging, materials, and equipment has formed, with 120 listed companies leading the way [3] - Major players like SMIC and Huahong Semiconductor have achieved significant milestones, such as breaking international monopolies and reaching international quality standards [3] - The average R&D intensity of integrated circuit companies on the STAR Market is 22.5%, exceeding the industry average by 10 percentage points [3] Biopharmaceutical Sector - The STAR Market's fifth listing standard has opened crucial financing channels for unprofitable innovative drug companies, with 19 out of 20 companies under this standard successfully launching self-developed drugs [4] - Zai Lab, the first unprofitable drug company listed on the STAR Market, has achieved multiple innovative drug approvals, establishing itself as a benchmark for internationalization in drug innovation [4] High-end Equipment Manufacturing - The STAR Market has created a collaborative innovation matrix in high-end equipment manufacturing, with 127 companies covering critical industries such as high-speed rail and nuclear power [5] - China Railway Signal & Communication Corporation holds a 65% market share in high-speed rail signal control systems, ensuring the safety of the national high-speed rail network [5] Social Impact - The technological breakthroughs from the STAR Market have translated into real benefits for the public, significantly reducing drug prices and improving access to medical resources [6] - Innovative drugs have substantially lowered the economic burden on patients, with some treatments seeing price reductions of over 75% [6] - Domestic medical equipment has improved accessibility, with companies like United Imaging Healthcare breaking international monopolies and producing high-end medical devices [7] Financial Performance - Over 60% of STAR Market companies have introduced cash dividend plans, totaling 38.8 billion yuan, with over 290 companies distributing more than 30% of their profits [9] - The board has also seen significant share buyback and increase plans, with a total amount nearing 38 billion yuan [9] Institutional Innovations - The STAR Market has implemented continuous institutional innovations to address the financing challenges of "light asset, high R&D investment" companies, allowing for a higher refinancing ratio [10] - The establishment of the "Sci-Tech Growth Layer" provides a transitional platform for unprofitable tech companies, enhancing their growth prospects [10] Long-term Vision - The STAR Market has become a core nurturing ground for new productive forces, with 379 companies recognized as national "little giants" and 415 as manufacturing "champions" [12] - The board's R&D investment reached 168 billion yuan, more than three times its net profit, reflecting a strong commitment to innovation [12] - The ongoing reforms aim to further unleash the potential of the STAR Market, enhancing its role in both technological advancement and societal value [13]

Core Viewpoint - The Sci-Tech Innovation Board (STAR Market) has successfully integrated technology innovation with capital markets over the past six years, supporting 589 high-tech and strategic emerging enterprises with a total market capitalization exceeding 7 trillion yuan and raising over 1.1 trillion yuan in IPO and refinancing funds [1][3][11]. Group 1: Market Development and Achievements - The STAR Market has become the preferred listing venue for China's hard technology companies, with over 80% of listed companies focusing on import substitution and self-control [1][3]. - The board has seen significant R&D investment, with cumulative R&D expenditures exceeding 700 billion yuan from 2019 to 2024, and a median R&D investment-to-revenue ratio of 12.6%, far surpassing other boards [3][4]. - The STAR Market has facilitated the listing of various innovative companies, including 120 in integrated circuits and over 110 in biomedicine, contributing to a robust industrial ecosystem [3][4]. Group 2: Policy and Regulatory Changes - Recent reforms, including the introduction of the "1+6" policy measures, aim to enhance the STAR Market's support for hard technology enterprises while ensuring investor protection [2][11][12]. - The establishment of a growth tier within the STAR Market is designed to accommodate unprofitable technology companies, reflecting a more inclusive regulatory environment [11][12]. Group 3: Investment Landscape - The average price-to-earnings (P/E) ratio of STAR Market companies has shown fluctuations, peaking at 94.63 times in 2020 and stabilizing at 52.35 times by July 2025, indicating a recovery in valuations [7]. - Institutional investor participation has increased, with over 60% of holdings in the STAR Market attributed to professional institutions, and a notable rise in long-term capital investment [9][10]. Group 4: Future Outlook - The STAR Market is expected to continue evolving, with a focus on optimizing support mechanisms for technology enterprises and enhancing the valuation framework for long-term R&D companies [13]. - There is anticipation for more high-quality technology firms to list, fostering a virtuous cycle among technology, industry, and finance, which will contribute to high-quality economic development in China [13].

Core Viewpoint - The July Purchasing Managers' Index (PMI) for strategic emerging industries shows a seasonal decline but has turned positive year-on-year, indicating resilience in industrial prosperity despite a slight month-on-month decrease [1][5][6]. Group 1: PMI Overview - The July EPMI decreased by 1.1 points to 46.8, with only the new materials sector remaining in the expansion zone among seven sub-industries, reflecting a reduction in the number of expanding sectors [1][5][9]. - The absolute prosperity level is 0.7 points higher than the same period last year, marking a transition from negative to positive year-on-year growth [1][8]. Group 2: Sub-Indicators Analysis - In July, production, product orders, and export orders in emerging industries fell by 1.3, 1.5, and 2.2 points respectively, with export orders declining for two consecutive months [2][9]. - The production-to-demand ratio remained stable at 2.2, fluctuating within a narrow range for five months [2][12]. - Financing conditions improved, with the difficulty of obtaining loans decreasing by 1.4 points in July [2][14]. - A notable positive signal is the stabilization of sales prices, which increased by 1.7 points, while purchase prices continued to decline [2][14]. Group 3: Sector-Specific Insights - The new materials sector has shown a continuous increase in prosperity for three months, with a July index above 50, indicating strong performance compared to other sectors [3][17]. - High-end equipment manufacturing and energy-saving environmental protection sectors maintained resilience, while the biotechnology and new energy vehicle sectors saw a decline in prosperity [3][17]. - Export orders for biotechnology and new energy vehicles fell significantly, by 17.7 and 10.1 points respectively [3][20]. Group 4: Market Implications - The EPMI data suggests a generally positive impact on the market, with the month-on-month decline being anticipated and the year-on-year increase indicating a slope lower than seasonal averages [4][22]. - The shift in key industry sales price indices from decline to increase reflects the effectiveness of "anti-involution" policies in stabilizing nominal growth [4][22].

Core Insights - The Sci-Tech Innovation Board (STAR Market) has achieved significant milestones in its six years, supporting technological innovation and fostering a vibrant ecosystem for "hard tech" companies [1][4][15] Group 1: Achievements and Innovations - STAR Market companies have consistently invested over 10% of their revenue in R&D, leading to a rapid pace of technological advancement [1] - Recent breakthroughs include the completion of Phase III clinical trials for a new cancer drug by Bai Li Tian Heng and FDA approval for a new drug by Di Zhe Pharmaceutical [2][3] - As of March 2024, STAR Market companies collectively applied for 29,41 patents, with over 80% being invention patents, showcasing their commitment to innovation [5] Group 2: Market Dynamics and Growth - The STAR Market has become a preferred platform for "hard tech" companies, with over 589 listed companies raising more than 1.1 trillion yuan through IPOs and refinancing [9] - Approximately 30% of STAR Market companies have products or projects that are industry-first, and over 80% focus on import substitution and self-sufficiency [6] - The market has seen a significant increase in the number of companies focusing on emerging industries such as AI, biotechnology, and high-end manufacturing, which now account for over 80% of listed firms [7] Group 3: Institutional Support and Reforms - The STAR Market serves as a "testbed" for capital market reforms, with various innovative mechanisms introduced to support the growth of tech companies [8][10] - Recent reforms include the establishment of a growth tier for unprofitable companies and the introduction of new standards to facilitate financing for innovative firms [14][15] - The market's structure encourages a healthy cycle of technology, industry, and capital, promoting collaboration among various stakeholders [11]